Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort

被引：0
|
作者：
Verstockt, B. [1 ,2 ]
Vieujean, S. [3 ]
Truyens, M. [4 ,5 ]
Julsgaard, M. [6 ]
Pugliese, D. [7 ]
Aslan, D. [1 ,8 ]
Prokopic, M. [8 ]
Lim, S. [9 ]
Vigano, C. [10 ]
Festa, S. [11 ]
Ramos, L. [12 ]
Garcia, M. J. [13 ]
Plaza, R. [14 ]
Noviello, D. [15 ]
Savarino, E. [16 ]
Drobne, D. [17 ]
Imperatore, N. [18 ]
Ribaldone, D. G. [19 ]
Van Dongen, J. [20 ]
Teich, N. [21 ]
Wahed, M. [22 ]
Barberio, B. [23 ]
Goren, I. [24 ,25 ]
机构：
[1] Univ Hosp Leuven, Dpt Gastroenterol & Hepatol, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Chron Dis & Metab, Translat Res Gastrointestinal Disorders, Leuven, Belgium
[3] Univ Hosp CHU Liege, Hepatogastroenterol & Digest Oncol, Liege, Belgium
[4] Ghent Univ Hosp, Dept Gastroenterol, Ghent, Belgium
[5] Univ Ghent, Dept Internal Med & Paediat, Ghent, Belgium
[6] Aarhus Univ Hosp, Gastroenterol, Aarhus, Denmark
[7] Fdn Policlin A Gemelli IRCSS, Gastroenterol, Rome, Italy
[8] Comenius Univ, Dept Gastroenterol, Jessenius Fac Med, Univ Hosp Martin, Bratislava, Slovakia
[9] Guys & St Thomas NHS Fdn Trust, Gastroenterol, London, England
[10] Univ Milano Bicocca, San Gerardo Hosp, Gastroenterol, Monza, Italy
[11] San Filippo Neri Hosp, Gastroenterol, Rome, Italy
[12] Hosp Univ Canarias Spain, Gastroenterol, Gran Canaria, Spain
[13] Hosp Univ Marques de Valdecilla, IDIVAL, Valdecilla, Spain
[14] Hosp Intana Leonor, Gastroenterol, Madrid, Spain
[15] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[16] Univ Paduo, Azienda Osped Padova, Gastroenterol, Padua, Italy
[17] Univ Med Ctr, Gastroenterol, Ljubiljana, Slovenia
[18] Cardarelli Hosp Naples, Gastroenterol, Naples, Italy
[19] Univ Torino, Gastroenterol, Turin, Italy
[20] AZ Sint Maarten, Gastroenterol, Mechelen, Belgium
[21] Int Gemeinschaftspraxis Verdauungs, Dpt Gastroenterol, Leipzig, Germany
[22] Chelsea & Westminster NHS Fdn Trust, Gastroenterol, London, England
[23] Univ Paduo, Azienda Osped Padova, Gastroenterol, Padua, Italy
[24] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[25] Cleveland Clin, Dept Inflammat & Immun, Lerner Res Inst, Cleveland, OH USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P674
引用
收藏
页码：805 / 805
页数：1
相关论文
共 50 条
  • [31] Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers
    Riviere, Pauline
    Kanters, Caitlyn
    Pellet, Gauthier
    Ni, Alexander
    Hupe, Marianne
    Aboulhamid, Nesrine
    Poullenot, Florian
    Bitton, Alain
    Zerbib, Frank
    Lakatos, Peter L.
    Afif, Waqqas
    Laharie, David
    Bessissow, Talat
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (06) : 923 - 931
  • [32] Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups - results from a 13-yr real-world retrospective study
    Majumder, S.
    Melanie, L.
    Joanne, D.
    Naveen, S.
    Quraishi, M. N.
    Cooney, R.
    Ghosh, S.
    Iacucci, M.
    Shivaji, U. N.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 603 - 604
  • [33] Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
    Ko, Yanna
    Paramsothy, Sudarshan
    Yau, Yunki
    Leong, Rupert W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (03) : 292 - 301
  • [34] Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry
    Filippini, Matteo
    Bazzani, Chiara
    Atzeni, Fabiola
    Puttini, Piercarlo Sarzi
    Marchesoni, Antonio
    Favalli, Ennio Giulio
    Caporali, Roberto
    Cavagna, Lorenzo
    Gorla, Roberto
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [35] Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases
    Attauabi, Mohamed
    Hoglund, Camilla
    Fassov, Janne
    Pedersen, Kenneth Bo
    Hansen, Heidi Bansholm
    Wildt, Signe
    Jensen, Michael Dam
    Neumann, Anders
    Lind, Cecilie
    Jacobsen, Henrik Albaek
    Popa, Ana-Maria
    Kjeldsen, Jens
    Pedersen, Natalia
    Molazahi, Akbar
    Haderslev, Kent
    Aalykke, Claus
    Knudsen, Torben
    Cebula, Wojciech
    Munkholm, Pia
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2021, 56 (09) : 1040 - 1048
  • [36] Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study
    Cottron, C.
    Treton, X.
    Altwegg, R.
    Reenaers, C.
    Amiot, A.
    Fumery, M.
    Vuitton, L.
    Peyrin-Biroulet, L.
    Bouguen, G.
    Dewit, O.
    Nancey, S.
    Caillo, L.
    Roblin, X.
    Beylot-Barry, M.
    Riviere, P.
    Laharie, D.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I502 - I502
  • [37] Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study
    Cottron, C.
    Treton, X.
    Altwegg, R.
    Reenaers, C.
    Amiot, A.
    Fumery, M.
    Vuitton, L.
    Peyrin-Biroulet, L.
    Bouguen, G.
    Dewit, O.
    Nancey, S.
    Caillo, L.
    Roblin, X.
    Beylot-Barry, M.
    Riviere, P.
    Laharie, D.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I502 - I502
  • [38] How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort
    Claudia Ott
    Angela Takses
    Florian Obermeier
    Elisabeth Schnoy
    Bernd Salzberger
    Martina Müller
    International Journal of Colorectal Disease, 2014, 29 : 1329 - 1338
  • [39] How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort
    Ott, Claudia
    Takses, Angela
    Obermeier, Florian
    Schnoy, Elisabeth
    Salzberger, Bernd
    Muller, Martina
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (11) : 1329 - 1338
  • [40] Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study
    Mocci, G.
    Cuomo, A.
    Allegretta, L.
    Aragona, G.
    Colucci, R.
    Della Valle, N.
    Ferronato, A.
    Forti, G.
    Gaiani, F.
    Graziani, M. G.
    Lorenzetti, R.
    Luzza, F.
    Penna, A.
    Pica, R.
    Piergallini, S.
    Rodino, S.
    Scarcelli, A.
    Zampaletta, C.
    Cicerone, C.
    Cocco, A.
    De Angelis, G.
    Donnarumma, L.
    Pranzo, G.
    Franceschi, M.
    Gallina, S.
    Grasso, G.
    Larussa, T.
    Luppino, I.
    Faggiani, R.
    Fanigliulo, L.
    Pagnini, C.
    Perazzo, P.
    Sacco, R.
    Sebkova, L.
    Serio, M. E.
    De Monti, A.
    Picchio, M.
    Elisei, W.
    Maconi, G.
    Tursi, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S536 - S537
12345